Professor Pat Price is an academic clinical oncologist specialising in PET based molecular imaging, advanced radiotherapy techniques and translational research in oncology.
Currently Professor Price is a visiting Professor in the Division of Surgery within the Department of Surgery and Cancer, Imperial College London.
Prof Price pioneered the use of PET molecular imaging for micro-dosing pharmacokinetic and pharmacokinetic studies of new cancer agents and has one of the best insights into the potential of the application of this technology for oncology drug development. Through the PET Research Advisory Company www.the-pra.co.uk, she provides advice to organisations on current and projected future investments in PET.
Professor Pat Price studied at Cambridge and King’s College Hospital Medical School. She trained in general medicine in Cambridge and in oncology at the Royal Marsden Hospital. She took a research position under a Cancer Research Campaign Clinical Fellowship at the Institute of Cancer Research, London, and won the Cambridge University prize for best laboratory based MD. She went on to work at the Hammersmith Hospital, London as a Senior Lecturer.
While at the Hammersmith she developed a research interest in molecular imaging for oncology. Professor Price pioneered the use of PET imaging to investigate how cancer drugs move in the body and the effect they have. She set up and headed the Medical Research Council and Cancer Research Campaign Positron Emission Tomography (PET) Oncology Programmes. She moved to Manchester in September 2000 to take up the Ralston Paterson Chair in Radiation Oncology and set up the new Wolfson Molecular Imaging Centre at the Christie Hospital.
Professor Price is a member of the American Association for Cancer Research (AACR) membership Development Committee. She is a member of a number of Cancer Research UK committees, and the Royal College of Radiologists Radiotherapy Development Board.
Previously she was president of the British Oncological Association and sits on the 2008 RAE sub-committee for Cancer. She established and chaired for 6 years, the European Organisation for Research and Treatment of Cancer (EORTC) Functional Imaging Group, and in 2005 established the UK National Cancer Research Institute (NCRI) Academic Clinical Oncology and Radiobiology Research Network (ACORRN) which aims to reinvigorate radiotherapy and radiobiology research in the UK. She has over 140 peer reviewed research publications and co-edits the UK standard oncology text book Treatment of Cancer.
Dr Matthew Krebs is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust.
Dr Krebs is also the Clinical Senior Lecturer in Experimental Cancer Medicine at the Christie Phase One Trials Unit at The Christie.
Dr Krebs obtained his Bachelor of Medicine and Bachelor of Surgery (MB ChB) at the University of Leicester in 2001. In 2005 he became a Member of Royal College of Physicians (London), UK. In 2011 he completed his PhD in Experimental Pharmacology and Circulating Biomarkers at the University of Manchester.
Dr Krebs was appointed as Consultant Medical Oncologist to the rapidly expanding Phase One Clinical Trials Unit at the Christie in 2014.
Dr Mark Harries is a Consultant Medical Oncologist based at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.
Dr Harries specialises in the treatment of Breast Cancer and Melanoma.
Mark graduated from Cambridge University and underwent clinical training at The Royal London Hospital. He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London.
Dr Harries is a member of the Association of Cancer Physicians, Royal College of Physicians, American Society of Clinical Oncology, European Society of Medical Oncology and the British Medical Association.
Dr Majid Kazmi is a Consultant Haematologist based at Guy’s & St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.
Dr Kazmi qualified from the University of Aberdeen in 1991 with Commendation. He has been a consultant in Haemato-oncology since 2001.
Currently Dr Kazmi is the Lead Cancer Clinician and Clinical Director of Oncology & Haematology at Guy’s & St Thomas’. He is also medical director for commercial activities at the Trust. He is Chair of the Haemato-oncology pathway group on behalf of the London Cancer Alliance covering the population of South London and NW London (5 million people).
His clinical interests include Myeloma where he has been the UK Chief Investigator for a number of national and international studies. He sits on the UK guidelines group for Myeloma and Amyloidosis. He has extensive experience in Transplantation and is the UK lead for transplantation in auto-immune diseases for EBMT (European Group for Blood and Marrow Transplantation).
Dr Kazmi is a member of European group for Blood and Marrow Transplantation (EBMT) and American Society of Haematology (ASH), American Society of Haematology, British Society of Marrow Transplantation and the European Group for Blood and Marrow transplantation.
Dr Maged Gharib is a Consultant Haematologist based at St Helen's and Knowsley Teaching Hospitals NHS Trust.
Dr Gharib graduated from Cairo University in 1990. He undertook 6 years of general medical training in Cairo then Coventry, before specialist Haematology training at University Hospitals of Edinburgh, Cardiff and Manchester.
Dr Gharib took his first Consultant Haematologist post at Alder Hey Hospital as a Paediatric Haematologist. He then moved to Manchester in 2006 to take up a consultant post in paediatric stem cell transplantation.
In 2010 he moved on to St Helens' Teaching Hospitals. In addition to his expertise in the management of a wide range of haematological malignancies (Lymphoma, Leukaemia and Myeloma), he is an expert in the management of cancer associated thrombosis (blood clots).
Dr Gharib is a member of the Royal College of Physicians; Royal College of Pathologists; British Society for Haematology and the European Haematology Association.
Dr Lucy Brazil is a Consultant Clinical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.
Dr Brazl has a special interest in neuro-oncology, in particular, the treatment of glioblastoma multiforme and low grade glioma (including oligodendroglioma). She trained in oncology at Royal Marsden Hospital and Guy's and St Thomas’ Hospitals. She was awarded an MD in 2007 for research into breast cancer genetics at the Institue of Cancer Research and Breakthrough Breast Cancer.
Dr Brazil is an active member of The National Cancer Institute Brain Tumour Clinical Studies Group, as well as The European Organisation for Research and Treatment of Cancer Brain Tumour Group. She is also Chairman of The Brain Tumour Palliative Care / Quality of Life subgroup.
Dr Brazil was Chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for Gliomas,
Chairman of the brain tumour Palliative care QOL sub-group, and Systemic Chemotherapy Neuro-oncology Research lead at Guy’s and St Thomas’.
Dr Kim Linton is a Consultant Medical Oncologist based at The Christie NHS Foundation Trust in Manchester.
Dr Linton was awarded a medical degree from the University of Cape Town in 1994 and emigrated to the UK in the following year. She was a senior house officer in both Oncology and Palliative Medicine at Cookridge Hospital and Wheatfields Hospice, Leeds between 1997-2000 and then went on to be a Specialist Registrar in Medical Oncology at The Christie in 2000. In 2007 She gained her PhD in molecular pathology from the University of Manchester. Dr Linton was appointed in 2009 as an honorary medical oncology consultant in Lymphoma at The Christie.
Dr Linton works as a Senior Lecturer and Honorary Consultant in Lymphoma at The University of Manchester and The Christie Foundation Trust in Manchester. She co-leads the Medical Oncology Lymphoma Team, caring for patients with all lymphoma diagnoses excepting those that are HIV associated.
Her main research interests include the technical development of gene expression technologies for formalin fixed paraffin embedded tissue, blood and tissue-based lymphoma biomarker research predominantly in rare lymphoma subtypes and in the prevention and early detection of late effects of treatment, and prognosis and treatment of lymphomas. She is a member of the NCRN lymphoma low grade and biology subgroups.
Dr Linton is a member of Royal College of Physicians, Association of Cancer Physicians, Medical Protection Society, National Cancer Research Network low grade and biology subgroups, MCRC Lymphoma Biobank Board, Salford Citizen Scientist Committee, Lymphoma Translational Research Group (chair), Christie Undergraduate Board and the Critical Care Delivery Group
As well as speaking English Dr Linton also speaks Afrikaans.
Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.
Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.
Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.
He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.
Professor Jonathan Waxman is Professor of Oncology at Imperial College London.
Prof Waxman practises as a general oncologist, treating patients with a wide range of malignancies. He specialises in urological oncology treating patients with prostate, kidney, bladder and testicular cancer and has developed new treatments for these conditions such as LHRH agonist therapy for prostate cancer.
He helped establish an All Party Parliamentary Group to improve cancer treatment and rationalise cancer research throughout the UK and has developed and led successful media campaigns to rationalise cancer treatments and change government health policy.
He has had many years experience in Medico-Legal work providing expert reports to plantiff and defendant and appearing as an expert witness. He has written a textbook of medical law and many medical textbook and research papers. Professor Waxman has written around 400 scientific research papers and chapters and 11 books on cancer.
Professor Jamie Cavenagh is a Professor of Haematology based at Barts Health NHS Trust.
Prof Cavenagh qualified with MB BS in 1985 from St Marys Hospital Medical School, London. He trained in clinical haematology at St Georges Hospital, The Royal Marsden Hospital and Barts and The London.
Professor Cavenagh was a Leukaemia Research Fund Scientific Training Fellow from 1992-1994 and he is currently the Chairman of the UK Myeloma Forum.